|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma显示文摘Hepatocellular carcinoma (HCC) accounts for the majority of primary liver cancers. To date, most patients with HCC are diagnosed at an advanced tumor stage, excluding them from potentially curative therapies (i.e., resection, liver transplantation, percutaneous ablation). Treatments with palliative intent include chemoembolization and systemic therapy. Among systemic treatments, the small-molecule multikinase inhibitor sorafenib has been the only systemic treatment available for advanced HCC over 10 years. More recently, other smallmolecule multikinase inhibitors (e.g., regorafenib, lenvatinib, cabozantinib) have been approved for HCC treatment. The promising immune checkpoint inhibitors (e.g., nivolumab, pembrolizumab) are still under investigation in Europe while in the US nivolumab has already been approved by FDA in sorafenib refractory or resistant patients. Other molecules, such as the selective CDK4/6inhibitors (e.g., palbociclib, ribociclib), are in earlier stages of clinical development, and the c- MET inhibitor tivantinib did not show positive results in a phase III study. However, even if the introduction of targeted agents has led to great advances in patient response and survival with an acceptable toxicity profile, a remarkable inter-individual heterogeneity in therapy outcome persists and constitutes a significant problem in disease management. Thus, the identification of biomarkers that predict which patients will benefit from a specific intervention could significantly affect decision-making and therapy planning. Germ-line variants have been suggested to play an important role in determining outcomes of HCC systemic therapy in terms of both toxicity and treatment efficacy. Particularly, a number of studies have focused on the role of genetic polymorphisms impacting the drug metabolic pathway and membrane translocation as well as the drug mechanism of action as predictive/prognostic markers of HCC treatment. The aim of this review is to summarize and critically discuss the pharmacogenetic literature evidences, with particular attention to sorafenib and regorafenib, which have been used longer than the others in HCC treatment. | Elena De Mattia Erika Cecchin Michela Guardascione Luisa Foltran Tania Di Raimo Francesco Angelini Mario D’Andrea Giuseppe Toffoli | 2019 | World Journal of Gastroenterology2019，25，29： | 8 |
| 2 | Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions显示文摘Pancreatic cancer(PDAC) is an aggressive and chemoresistant disease, representing the fourth cause of cancer related deaths in western countries. Majority of patients have unresectable, locally advanced or metastatic disease at time of diagnosis and the 5-year survival rate in these conditions is extremely low. For more than a decade gemcitabine has been the cornerstone of metastatic PDAC treatment, although survival benefit was very poor. PDAC cells are surrounded by an intense desmoplastic reaction that may create a barrier to the drugs penetration within the tumor. Recently PDAC stroma has been addressed as a potential therapeutic target. Nano albumin bound(Nab)-paclitaxel is an innovative molecule depleting tumor stroma, through interaction between albumin and secreted protein acidic and rich in cysteine. Addition of nab-paclitaxel to gemcitabine has showed activity and efficacy in metastatic PDAC first-line treatment improving survival and overall response rate vs gemcitabine alone in the MPACT phase Ⅲ study. This combination represents one of the standards of care in advanced PDAC therapy and is suitable to a broader spectrum of patients compared to other schedules. Nab-paclitaxel is under investigation as a backbone of chemotherapy in novel combinations with target agents or immunotherapy in locally advanced or metastatic PDAC. In this article, we provide an updated and critical overview about the role of nab-paclitaxel in PDAC treatment based on the latest advances in preclinical and clinical research. Furthermore, we focus on the use of nab-paclitaxel within the context of metastatic PDAC treatment landscape and we discuss about future implications in the light of current clinical ongoing trials. | Guido Giordano Massimo Pancione Nunzio Olivieri Pietro Parcesepe Marianna Velocci Tania Di Raimo Luigi Coppola Giuseppe Toffoli Mario Rosario D’Andrea | 2017 | World Journal of Gastroenterology2017，23，32： | 7 |
| 3 | Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment显示文摘 | Elena De Mattia Giuseppe Toffoli Jerry Polesel Mario D’Andrea Giuseppe Corona Vittorina Zagonel Angela Buonadonna Eva Dreussi Erika Cecchin | 2013 | Pharmacogenetics and Genomics2013，，10： | 2 |
| 4 | Potential role of TRAIL in the management of autoimmune diabetes melli-tus显示文摘 | Bernardi S1 Norcio A Toffoli B | 2012 | Curr Pharm Des2012，18，35： | 1 |
| 5 | Human full-length osteoprotegerin induces the proliferation of ro- dent vascular smooth muscle cells both in vitro and in vi-vo显示文摘 | CANDIDO R TOFFOLI B CORALLINI F | 2010 | J Vasc Res2010，47，3： | 1 |
| 6 | Pharmacogenetics of irinotecan 显示文摘 | Toffoli G Cecchin E Corona G | 2003 | Curr Med Chem Anticancer Agents2003，3，3： | 1 |
| 7 | Intermittent hypoxia is an angiogenic inducer for endothelial cells:role of HIF-1显示文摘 | Toffoli S Roegiers A Feron 0 | | 0，，： | 1 |
| 8 | Pulsatile ocular blood flow variations with axial length and refractive error 显示文摘 | Ravalico G Pastori G Croce M Toffoli G | 1997 | Ophthalmologica1997，211，5： | 1 |
| 9 | Pharmacology of epidermal growth factor inhibitors 显示文摘 | Toffoli G De Mattia E Cecchin E | 2007 | Int J Biol Markers2007，22，1： | 1 |
| 10 | Drug interactions among the epidermal growth factor receptor inhibitors,other biologics and cytotoxic agents显示文摘 | Visentin M Biason P Toffoli G | 2010 | Pharmacol Ther2010，128，1： | 1 |
| 11 | Invertible cellular automata:A review 显示文摘 | Toffoli T Margolus N H | 1990 | Physica D: Nonlinear Phenomena1990，45，1： | 1 |
| 12 | MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyelophosphamide,methotrexate,and fluorouracil(CMF)显示文摘 | Toffoli G Veronesi A Boincehi M | 2000 | Ann Oncol2000，11，3： | 1 |
| 13 | On the variability of sea drag in finite water depth显示文摘 | Toffoli A Loffredo L Roy P L | 2012 | J Geophys Res2012，117，11： | 1 |
| 14 | The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer显示文摘 | Toffoli Cecchin G Corona E | 2006 | J Clin Oncol2006，24，19： | 1 |
| 15 | Oral idarubicin (IDA) for the treatment of hepatocellular carcinoma显示文摘 | Tumolo S Toffoli G Bearz A | | 0，，： | 1 |
| 16 | Image sequence processing for videowall visualization显示文摘 | Skarabot A Ramponi G Toffoli D | 2000 | Proceedings of SPIE2000，3961，： | 1 |
| 17 | Metabolomics Biomarkers of Frailty in Elderly Breast Cancer Patients显示文摘 | Giuseppe Corona Jerry Polesel Lucia Fratino Gianmaria Miolo Flavio Rizzolio Diana Crivellari Riccardo Addobbati Silvia Cervo Giuseppe Toffoli | 2014 | J Cell Physiol2014，，7： | 1 |
| 18 | Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy显示文摘 | Cocchietto M Zorzin L Toffoli B | 2008 | Diabetes Metab2008，34，61： | 1 |
| 19 | Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line显示文摘 | Toffoli G Corona G Gigante M | 2006 | Eur J Cancer2006，32，9： | 1 |
| 20 | Pharmacogenomics and stomach cancer显示文摘 | Toffoli G Cecchin E | 2004 | Pharmacogenomics2004，5，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员